League of International Veterinary Educational Specialists

佐藤 雅彦

職歴

2005年 　　 　岩手大学農学部獣医学科卒業
2005-2007年　東京都内動物病院勤務
2007-2011年　東京大学大学院農学生命科学研究科獣医学専攻博士課程
2011-2012年　米国Fred Hutchinson Cancer Research Center 研究員
2012-2013年　東京大学大学院農学生命科学研究科農学特定研究員
2013-2014年　コロラド州立大学大学院
2014-2018年　コロラド州立大学小動物内科レジデント　米国獣医内科学専門医取得（小動物内科）
2018-2020年　東京大学大学院農学生命科学研究科特任准教授
2020年-　　　どうぶつの総合病院内科主任

論文執筆

  1. Sato M, Shropshire SB, Veir JK, Lappin MR. No recrudescence of ehrlichiosis in dogs experimentally inoculated with Ehrlichia canis, treated, and then immune suppressed during the acute or subclinical phases. J Vet Intern Med., in press
  2. Graham JA, Sato M, Moor AR, McGrew AK, Ballweber LR, Byas AD, Dowers KL.
    Strongyloides stercoralis disseminated infection in a dog treated with budesonide J Am Vet Med Assoc., 254;974-978, 2019
  3. Sato M, Mochizuki H, Goto-Koshino Y, Fujiwara-Igarashi A, Takahashi M, Ohno K, Tsujimoto H. Prognostic significance of hypermethylation of death-associated protein kinase(DAPK) gene CpG island in dogs with high-grade B-cell lymphoma. Vet Comp Oncol., 16;409-415, 2018
  4. Sato M, Veir JK, Legare M, Lappin MR. A retrospective study on the safety and efficacy of leflunomide in dogs. J Vet Intern Med., 31;1502-1507, 2017.
  5. Sato M, Yamazaki J, Goto-Koshino Y, Setogushi A, Takahashi M, Baba K, Fujino Y, Ohno K, Tsujimoto H. Minimal residual disease in canine lymphoma: an objective marker to assess tumor cell burden in remission. Review. Vet J., 215:38-42, 2016
  6. Sato M, Mochizuki H, Goto-Koshino Y, Fujiwara-Igarashi A, Takahashi M, Fujino Y, Ohno K, Tsujimoto H. Hypermethylation of the death-associated protein kinase CpG island in dogs with canine B-cell lymphoid tumors. Vet Immunol Immunopathol., 161:222-231, 2014
  7. Sato M, Storb R, Loretz C, Stone D, Mielcarek M, Sale GE, Rezvani AR, Graves SS. Inducible costimulatory (ICOS) up-regulation on activated T-cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target. Transplantation, 96:34-41,2013
  8. Sato M, Yamazaki J, Goto-Koshino Y, Takahashi M, Fujino Y, Ohno K, Tsujimoto H. The prognostic significance of minimal residual disease in the early phases of chemotherapy in dogs with high-grade B-cell lymphoma. Vet J., 195:319-324, 2012
  9. Sato M, Kanemoto H, Kagawa Y, Kobayashi T, Goto-Koshino Y, Mochizuki H, T5kahashi M, Fujino Y, Ohno K, Tsujimoto H. Evaluation of prognostic significance of BCL6 gene expression in canine high-grade B-cell lymphoma. Vet J., 191:108-114, 2012
  10. Sato M, Yamazaki J, Takahashi M, Goto-Koshino Y, Fujino Y, Ohno K, Tsujimoto H. Evaluation of cytoreductive efficacy of vincristine, cyclophosphamide, and doxorubicin in dogs with lymphoma by measuring the number of neoplastic lymphoid cells with real-time polymerase chain reaction. J Vet Intern Med., 25:285-291,2011
  11. Sato M, Yamazaki J, Takahashi M, Goto-Koshino Y, Fujino Y, Ohno K, Tsujimoto H. Increase in minimal residual disease (MRD) in peripheral blood before clinical relapse in dogs with lymphoma that achieved complete remission after chemotherapy. J Vet Intern Med., 25:292-296, 2011
  12. Sato M, Goto-Koshino Y, Mochizuki H, Fujino Y, Ohno K, Tsujimoto H. Perfusion method for harvesting bone marrow cells from dogs. Am J Vet Res., 72:1344-1348, 2011
  13. Sato M, Goto-Koshino Y, Kanemoto H, Mochizuki H, Fujino Y, Ohno K, Tsujimoto H. Characterization of canine BCL6 cDNA and detection systems for its protein expression. Vet Immunol Immunopathol., 140:166-169, 2011